Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...
Some consider the regular feeding of late-stage dementia patients to be nonnegotiable. Others see it as extending life ...
The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...
Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation.
Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...
The idea is straightforward: Take a blood test now, even without symptoms, and learn if you could some day develop ...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
As dementia rates continue to climb across Ohio — particularly in the Mahoning Valley — a new hands-on training is helping ...
Initial prescriptions for medications affecting cognition, such as antipsychotics, are disproportionately likelier to come from acute and post-acute settings such as emergency rooms, hospitals, and ...
Cognitive exercises offered by a bot named Sunny, paired with telehealth visits, can be “physical therapy for the brain.” ...
After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...
Researchers at Washington University School of Medicine in St. Louis analyzed how long 282 Alzheimer’s patients were able to continue living independently after taking two specific treatments: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results